Healthcare reforms drag on Abbott's Q1 profits and full-year targets
This article was originally published in Scrip
Executive Summary
Abbott Laboratories' pharmaceutical business rose by 13% in the first quarter thanks to double-digit sales growth of Humira (adalimumab) and its lipid management franchise. However, the firm's net income fell and earning expectations were lowered due to the recent US healthcare reform legislation and acquisitions.